Q3 2025 saw resumed growth and improved results, with strong momentum in HealthCare and AirCare, new international partnerships, and significant orders in Asia. Despite lower year-to-date sales, cost reductions and capital raises support a positive outlook for 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.